IFIH1 and myositis disease: Therapeutically, serology predicts response more reliably than clinical labels: interferon-related signatures respond to JAK or IFN-blockade; anti-Scl-70 aligns with antifibrotics and mycophenolate; anti-MDA5 or anti-SRP myositis requires combination regimens rather than steroids alone.